Supports investigator-initiated, milestone-driven clinical trials requiring enhanced oversight for up to 7 years, with mechanistic studies as applicable and one trial per application.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision) | February 5, 2028 (New) | March 5, 2028 (Renewal/Resubmission/Revision) | June 5, 2028 (New) | July 5, 2028 (Renewal/Resubmission/Revision) | October 5, 2028 (New) | November 5, 2028 (Renewal/Resubmission/Revision) | February 5, 2029 (New) | March 5, 2029 (Renewal/Resubmission/Revision) | June 5, 2029 (New) | July 5, 2029 (Closing; Renewal/Resubmission/Revision)
Funding Amounts: No budget limit; requests must reflect project needs. Most trials: up to 5 years; maximum: 7 years.
Summary: Supports implementation-ready, investigator-initiated clinical trials requiring enhanced oversight in NIAID research areas, with mechanistic studies where applicable.
Key Information: Only one clinical trial per application; all trial planning must be completed before submission.
The National Institute of Allergy and Infectious Diseases (NIAID) supports milestone-driven clinical trials addressing prevention, diagnosis, treatment, and disease mechanisms in infectious, allergic, and immunologic diseases. This U01 cooperative agreement is intended for investigator-initiated trials that cannot or will not be conducted through existing NIAID-supported networks or infrastructure. Trials must be ready for implementation, with documentation demonstrating readiness.
The program supports trial conduct, completion, analysis, and related activities, including recruitment, study products, laboratory work, monitoring, regulatory activities, and final reporting. Enhanced oversight applies to non-routine interventions, unlicensed products, licensed products used for unapproved indications, or trials requiring IND/IDE oversight. NIAID staff will have substantial scientific and programmatic involvement. A single platform trial, multiple interventions, or sequential stages within one trial are permitted.